局部复发前列腺癌的容积旋转调强放疗再照射
本研究纳入既往接受过放疗且经11C-胆碱正电子发射断层扫描证实局部复发的前列腺癌患者,采用无均整器技术的图像引导容积旋转调强放疗进行立体定向再照射,5次分割完成。23例患者再照射中位总剂量25 Gy,全部出现生化缓解,急性泌尿生殖系统毒性以1-2级为主,2年生化无复发生存率41.7%,2年局部控制率58.1%。
要点
- 再照射采用无均整器技术图像引导容积旋转调强放疗,5次分割,中位总剂量25 Gy。
- 全部23例患者出现生化缓解,急性泌尿生殖系统毒性以1-2级为主(13例,56.5%)。
- 中位随访33个月,中位生化无复发生存19个月,2年生化无复发生存率41.7%。
核心结论
- 对既往接受过放疗的前列腺癌患者进行再照射是一种有价值的选择,可安全考虑用于推迟激素治疗开始。
研究设计与样本
- 本研究为再照射研究,纳入既往接受过放疗、出现生化复发且11C-胆碱正电子发射断层扫描显示局部复发的前列腺癌患者。
- 再照射采用图像引导容积旋转调强放疗结合无均整器技术的立体定向治疗,5次每日分割。
- 共23例患者接受前列腺、前列腺床或前列腺及局部复发灶再照射。
主要发现
- 再治疗中位总剂量为25 Gy,分5次完成。
- 全部病例观察到生化缓解。
- 急性毒性主要为泌尿生殖系统1至2级(n=13;56.5%),1例(4.3%)出现3级血尿。
- 晚期泌尿生殖系统1级毒性4例(17.4%),3级1例(4.3%,尿道梗阻)。
- 胃肠道毒性可忽略不计;回归分析显示仅距初次放疗的较短时间(月)与急性泌尿生殖系统毒性显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study explores the efficacy and safety of reirradiation with modern radiation therapy techniques in patients previously irradiated for prostate cancer and affected by local relapse of disease. METHODS AND MATERIALS: Patients affected by previously irradiated prostate cancer were enrolled in this reirradiation study if they had a biochemical relapse and a 11C-choline positron emission tomography scan revealing the presence of a local recurrence of disease. Reirradiation consisted of a stereotactic treatment delivered by image guided radiation therapy-volumetric modulated arc therapy with flattening filter-free technology in 5 daily fractions. RESULTS: Twenty-three patients underwent reirradiation to the prostate, prostatic bed, or prostate and local recurrence. Re-treatment consisted of a median total dose of 25 Gy in 5 fractions. A biochemical response was observed in all cases. Acute toxicity was mainly genitourinary (GU) grade 1 to 2 (n = 13; 56.5%). One patient (4.3%) had grade 3 hematuria. A grade 1 GU late toxicity was registered in 4 patients (17.4%) and grade 3 in 1 patient (4.3%, urethral obstruction). Gastrointestinal toxicity was negligible. Regression analysis showed that only a short elapsed time in months from primary radiation therapy was significantly correlated with acute GU toxicity. After a median follow-up of 33 months (range, 5-58 months), the median biochemical recurrence-free survival was 19 months, and the 2-year biochemical recurrence-free survival (BRFS) was 41.7%. Median local control was 30 months; the 2-year local control rate was 58.1%. CONCLUSIONS: Reirradiation of patients with prostate cancer who underwent previous radiation therapy is a valuable option that can be safely considered to delay the beginning of hormonal treatment.
引用
- D'Agostino GR, Di Brina L, Mancosu P, et al. Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. Int J Radiat Oncol Biol Phys. 2019. PMID: 30825495. doi:10.1016/j.ijrobp.2019.02.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。